biostudies-literatureWan YProjects of the Shanghai Committee of Science and TechnologyProjects of National Science Foundation of ChinaMedical Engineering Cross Research Fund of Shanghai Jiao Tong UniversityMedical Engineering Cross Research Fund of University of Shanghai for Science and TechnologyShanghai Demonstration Project of Cooperative Diagnosis and Treatment for Major Difficult Diseases with integrative modern and traditional Chinese medicineNational Key Research and Development Program of ChinaInnovative research team of high-level local universities in Shanghai11572-11580https://www.ebi.ac.uk/biostudies/studies/S-EPMC12367974biostudies-literatureUnknown62(9)Levodopa induced dyskinesia (LID) is a serious side effect of levodopa treatment in Parkinson's disease (PD), with limited interventions. Understanding the genetic impact on LID would help inform future intervention studies. We performed integrative genomic analysis approaches to identify the genetic determinants of LID in a Chinese multi-center prospective, observational PD cohort. In this cohort, 46 of 315 PD patients developed LID during 2.5 years of follow-up. First, we performed a genome-wide association study (GWAS) in this cohort, followed by a meta-analysis integrating our GWAS summary data with additional data of European ancestry. Both GWAS analyses identified the Bromodomain Containing 3 (BRD3) as a LID susceptibility gene (P < 5 × 10^-8); however, the genetic variantsMolecular neurobiologyIntegrative Approaches Identify Genetic Determinants of Levodopa Induced Dyskinesia.PMC12367974SHSMU-ZDCX202119012017YFC131030022Y1190410081974173ZY(2021-2023)-0207-01-03YG2023ZD122023GD-XH06ZShao JZhang KWan YLi QLiu SLi WYe MLiu ZZhang XLuo WGuo DXie ARong LfalseIntegrative Approaches Identify Genetic Determinants of Levodopa Induced Dyskinesia.Levodopa induced dyskinesia (LID) is a serious side effect of levodopa treatment in Parkinson's disease (PD), with limited interventions. Understanding the genetic impact on LID would help inform future intervention studies. We performed integrative genomic analysis approaches to identify the genetic determinants of LID in a Chinese multi-center prospective, observational PD cohort. In this cohort, 46 of 315 PD patients developed LID during 2.5 years of follow-up. First, we performed a genome-wide association study (GWAS) in this cohort, followed by a meta-analysis integrating our GWAS summary data with additional data of European ancestry. Both GWAS analyses identified the Bromodomain Containing 3 (BRD3) as a LID susceptibility gene (P < 5 × 10^-8); however, the genetic variants2025-01-01T00:00:00Z2025 Sep2026-05-29T17:17:06.795Z2026-04-08T05:25:11.189ZS-EPMC123679744029930010.1007/s12035-025-04930-5